CNSYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
CERENOME, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.65−0.05 (-2.94%)
Close on Oct 19, 2026
- Market cap
- $11.38M
- P/E (TTM)
- –
- Dividend yield
- –
CERENOME, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2023 | FY2022 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant [Member] | $4.91M | $224.00K | – | – | – | – | – | – | – | – | 100.0% | +2093.3% |
| Consumable [Member] | – | – | $2.17M | $1.92M | – | – | – | – | – | – | – | – |
| Device [Member] | – | – | $225.00K | $576.00K | – | – | – | – | – | – | – | – |
| Other Products [Member] | – | – | $277.00K | $195.00K | – | – | – | – | – | – | – | – |
| Product revenue [Member] | – | – | $2.67M | $2.69M | – | – | – | – | – | – | – | – |
| License revenue [Member] | – | – | $1.00M | $0 | – | – | – | – | – | – | – | – |
| Royalty [Member] | – | – | $1.00M | – | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2023 | FY2022 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America [Member] | – | – | – | – | – | – | $894.00K | $1.08M | $1.14M | $1.35M | – | – |
| Europe [Member] | – | – | – | – | – | $675.00K | $649.00K | $1.95M | $2.00M | $1.97M | – | – |
| Other countries [Member] | – | – | – | – | – | – | $485.00K | $2.69M | $1.21M | $1.46M | – | – |
| Japan [Member] | – | – | – | – | – | – | – | $2.11M | $4.35M | $3.20M | – | – |
| Japan | – | – | $2.06M | $1.92M | $3.28M | $2.39M | $3.07M | $1.45M | $4.35M | – | – | – |
| Americas [Member] | – | – | $293.00K | $345.00K | $936.00K | $982.00K | $1.22M | $1.15M | – | – | – | – |
| Asia Pacific [Member] | – | – | $50.00K | $76.00K | $62.00K | $787.00K | $12.00K | $2.57M | – | – | – | – |
| EMEA [Member] | – | – | $270.00K | $344.00K | $379.00K | $675.00K | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Cerenome's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.